NasdaqGS:ARWRBiotechs
Is Arrowhead a Bargain After Clinical Trial Progress Fuels 168% Jump in 2025?
If you have ever wondered whether Arrowhead Pharmaceuticals is truly a bargain or just looks like one, you are in the right place. Let’s dig into what the numbers really say about its value.
The stock has soared recently, climbing 30.3% in the past week, 24.6% over the past month, and an astonishing 168.2% year-to-date. This suggests that investor optimism and perhaps risk perceptions have shifted quickly.
Much of this excitement comes after Arrowhead announced promising clinical trial...